logo
Alex's Lemonade Stand Foundation celebrates 25 years of impact, inspiration benefitting children with cancer

Alex's Lemonade Stand Foundation celebrates 25 years of impact, inspiration benefitting children with cancer

CBS News13 hours ago

It was 25 years ago that Alex Scott held her first lemonade stand. Today, the foundation in her name has raised more than $300,000,000.
The little lemonade girl has had quite an impact on the world and children with cancer, kids like Philip Steigerwald.
"I really thought that he was going to die, and I had to come to terms with that," said Wendy Steigerwald, Philip's mother.
But Philip Steigerwald is alive because of Alex's Lemonade Stand Foundation.
Right before his third birthday, he was diagnosed with neuroblastoma –the same cancer Alex Scott had.
CBS Philadelphia
"I remember when he was getting the chemo, I was meeting with somebody about you know, all the troubles that we were having, and I remember saying to her, 'We could have had a good life,' and she's like, 'Why do you say that?' I said, 'Well, cause he's dying, he'll be dead,'" Wendy Steigerwald said.
After grueling treatments, doctors told the Steigerwalds that there was nothing more they could do. That is, until they learned of a clinical trial at the Children's Hospital of Philadelphia, partly funded by Alex's Lemonade Stand Foundation.
"It's been a game changer. Kids who were destined to die are alive today," Dr. Yael Mossé, with the Children's Hospital of Philadelphia.
"Every morning he would take a pill, that's all he did, and it worked, it worked. I mean, it was a miracle," Wendy Steigerwald said.
Philip Steigerwald is not the only child alive today because of Alex and the foundation created in her name.
CBS Philadelphia
Brynn was part of a clinical trial in Georgia, partially funded by Alex's Lemonade Stand Foundation. She gets scans every six months, and a member of her family said things have been amazing since they ended the trial.
Lincoln and Abbie were in that trial. Lincoln is cancer-free! Plus, Abbie's tumor is stable, and she has a Master's degree and volunteers at a camp for children with cancer.
CBS Philadelphia
Those clinical trials, those miracles started with Alex Scott and her idea for a front-yard lemonade stand. She wanted to help all kids with cancer, not just neuroblastoma.
"I thought we might find a cure for her," said Liz Scott, Alex's mother. "We knew a lot of kids with neuroblastoma, and I felt like it was something that we needed to put all the funding into. But Alex very smartly told me that that was selfish and that all kids want their cancer to go away."
"If Alex didn't push us to fund all types of childhood cancer research, we wouldn't be where we are today," Jay Scott said. "Because we would be a neuroblastoma organization. We would be much smaller. We would have been unable to help as many kids as we've been able to help."
CBS Philadelphia
The Alex's Lemonade Stand Foundation has funded 1,500 medical research grants at 150 institutions, and there are more than 240 ongoing clinical trials that are funded by them each year.
"If you're doing pediatric cancer research, you come to [the] Alex Lemonade Stand Foundation. We couldn't do our work without this kind of support," said Dr. Leonard Zon with Boston Children's Hospital.
Twenty-five years of making a difference, better treatments and safer cures. Twenty-five years of offering hope.
"That's where your hope comes from," Liz Scott said. "That there's going to be something new in the pipeline that your child is going to receive that's going to make their cancer go away. It didn't happen for Alex, but the fact that it's happening for other kids now because of Alex is beyond anything I can express what that means."
"Wendy would always say 'Show me one kid that survived this,' and that's what – we didn't have any hope and now Philip, is that hope for parents that are going through it now," Philip Steigerwald's father said.
CBS Philadelphia

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Avelumab Plus Axitinib Shows Promise in Advanced GIST
Avelumab Plus Axitinib Shows Promise in Advanced GIST

Medscape

time17 minutes ago

  • Medscape

Avelumab Plus Axitinib Shows Promise in Advanced GIST

Combination therapy with avelumab plus axitinib demonstrated a clinical benefit in patients with advanced gastrointestinal stromal tumour (GIST), achieving a 69.6% disease control rate and a 57.1% progression-free survival (PFS) rate at 3 months. METHODOLOGY: Researchers conducted a phase 2 trial to evaluate the safety and efficacy of avelumab in combination with axitinib among 56 patients with unresectable/metastatic GIST (median age, 60 years) after the failure of standard therapy. Participants received avelumab 10 mg/kg intravenously every 2 weeks combined with axitinib 5 mg orally twice daily. The primary endpoint was the 3-month PFS rate; key secondary endpoints included overall survival, disease control rate, duration of response, and adverse events (AEs). The median follow-up duration was 27.4 months. TAKEAWAY: The PFS rate at 3 months was 57.1%, the median PFS was 4.6 months, and the median overall survival was 14.2 months. A partial response was achieved in 8.9% of patients, and the median duration of response was 18.5 months. Stable disease was observed in 60.7% of patients, corresponding to a disease control rate of 69.6%. AEs occurred in 94.6% of patients, with 30.4% experiencing grade 3 or higher events. The most common treatment-related AEs were diarrhoea (33.9%), thyroid dysfunction (30.4%), hypertension (25%), palmar-plantar erythrodysesthesia (23.2%), myalgia (17.9%), and dysphonia (17.9%). IN PRACTICE: "The AXAGIST trial is the largest prospective study evaluating the efficacy of the combination of immune checkpoint inhibitor and a multikinase inhibitor in patients with advanced/metastatic GIST. These results provide unique data on the activity of axitinib in GIST patients, which in combination with avelumab, resulted in long-term clinical benefit in a significant subset of patients," the authors wrote. SOURCE: This study was led by Piotr Lukasz Rutkowski, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. It was published online on June 06, 2025, in the European Journal of Cancer . LIMITATIONS: This study lacked a comparator arm, which made it impossible to conclude whether the addition of avelumab improves the antitumour activity of axitinib. DISCLOSURES: This research and drug supply were financially supported by Pfizer, as part of an alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc. Several authors declared receiving honoraria or having other ties with various sources.

Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions

Associated Press

time20 minutes ago

  • Associated Press

Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 16, 2025-- Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients. 1 The findings show Thermo Fisher's integrated services can potentially reduce drug development timelines by up to nearly three years, representing significant time savings on the average 10 to 15 years it takes to commercialize a new drug. Streamlining drug development is crucial for biotech and biopharma companies facing high development costs, regulatory complexity and the urgent need to bring safe, new medicines to market more quickly. Drug developers traditionally have relied on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions; however, this decentralized approach leads to inefficiency, miscommunication and delay. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue resulting from shortened market exclusivity and deferred market entry. 2 The Tufts CSDD study demonstrates that working with an integrated partner to provide contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can help speed and streamline the complex journey of drug development. Accelerator™ Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development. To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies. 'This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,' said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. 'Through Accelerator Drug Development, we are well positioned to bring customizable, end-to-end solutions and world-leading expertise to our customers, and we're proud of the capabilities we've built to meet customer and patient needs.' The Tufts CSDD study reported that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months. Researchers also found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, a return on investment of up to 113 times the initial investment. In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication. 'This study,' the authors wrote, 'demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.' The study's lead author, Joseph DiMasi, Ph.D., director of economic analysis and research associate professor, Tufts University, said, 'The cost of developing new drugs is exacerbated by operational inefficiencies from the siloing of clinical research, drug manufacturing and supply chain functions. Our findings underscore the strategic importance of integrated services as a driver of value. Drug sponsors considering this approach should consider the degree of integration that would drive the most value for their programs. Our study reveals that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.' To learn more, please visit Thermo Fisher Scientific's website. Additionally, Thermo Fisher will showcase its latest innovative and flexible solutions in support of biotechnology and biopharmaceutical companies at every stage of their drug development journey during the 2025 BIO International Convention, June 16-19 (booth #2953). Leaders from across the organization will also participate in a series of panel discussions that will highlight industry trends, strategies for sustainability and the value of collaboration to bring medicines to market faster. 1 The research was supported in part by a grant from Thermo Fisher Scientific to the Tufts Center for the Study of Drug Development. Tufts CSDD maintains a strong reputation for scholarly and objective insights drawn from hard evidence. The results of all research conducted by Tufts CSDD remain independent and are published in peer-reviewed and trade journals. The study, which researchers believe to be the first of its kind, modeled the net financial benefit of integrated CDMO-CRO services Thermo Fisher provided to customers in recent years using a risk-adjusted, discounted cash flow analysis (also known as an expected net present value analysis). While the study focused on oncology drug development scenarios, the findings may have applications more broadly across other therapeutic areas. 2 Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. 'Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.' Annals of Operations Research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on CONTACT: Media Contact Information: Ned Glascock E-mail:[email protected] Website: Morton E-mail:[email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Thermo Fisher Copyright Business Wire 2025. PUB: 06/16/2025 08:15 AM/DISC: 06/16/2025 08:14 AM

Aspirus Health starts expansion of the Aspirus Houghton Clinic
Aspirus Health starts expansion of the Aspirus Houghton Clinic

Yahoo

timean hour ago

  • Yahoo

Aspirus Health starts expansion of the Aspirus Houghton Clinic

Aspirus Health has commenced construction on its $5m renovation and expansion at Aspirus Houghton Clinic to improve healthcare efficiency, access, and patient experience in the Upper Peninsula, Michigan, US. The construction is led by the company in collaboration with Miron Construction and Plunkett Raysich Architects. Site preparation and fencing installation works commenced last month. This expansion of the clinic is a response to the growing demand for improved healthcare services. Aspirus Health regional clinics director Laura Brogan said: 'This facility is designed to enhance our patients' overall experience by focusing on team-based care and efficiency—from the moment you enter the parking lot, throughout your visit with our care teams, and even as you leave the facility.' The renovation and expansion project includes the construction of two new procedure rooms, 13 new exam rooms, a drive-through pharmacy, and a redesigned central registration and waiting area. It will also update the existing space to better serve the community. This project follows Aspirus Health's recent announcement of a $31.1m investment to expand Aspirus Keweenaw Hospital in Laurium, Michigan. Aspirus Keweenaw Hospital chief administrative officer Melanee Tiura said: 'We're excited to enhance and broaden local care while also contributing to the growth of the local economy. 'We are committed to continuously improving healthcare for our community. While the clinic has served this community for many years, it became clear that to meet the growing needs of our patients, we needed to expand services and capacity.' The Aspirus Houghton Clinic's project is anticipated to be completed in January 2026. "Aspirus Health starts expansion of the Aspirus Houghton Clinic" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store